 Date: 2014-11-03 11:26:24Organic chemistry Medicine Amides Merck Oxadiazoles Raltegravir Integrase Dolutegravir ViiV Healthcare Integrase inhibitors Chemistry Organofluorides | |  Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside
Add to Reading ListSource URL: shionogi616.tew-staging.comDownload Document from Source Website File Size: 46,87 KBShare Document on Facebook
|
